TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of “Hold” from Analysts

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) have been assigned an average rating of “Hold” from the seven research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $6.60.

Several brokerages recently issued reports on TCRX. Morgan Stanley lowered shares of TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a report on Friday, November 14th. Weiss Ratings restated a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Thursday. Needham & Company LLC decreased their target price on shares of TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, November 4th. HC Wainwright lowered their price target on shares of TScan Therapeutics from $10.00 to $7.00 and set a “buy” rating for the company in a report on Thursday, November 13th. Finally, BTIG Research downgraded TScan Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, November 4th.

Insider Buying and Selling

In other news, major shareholder Lynx1 Capital Management Lp bought 80,069 shares of the company’s stock in a transaction on Friday, December 19th. The stock was purchased at an average cost of $0.90 per share, for a total transaction of $72,062.10. Following the completion of the transaction, the insider owned 7,937,416 shares of the company’s stock, valued at $7,143,674.40. This trade represents a 1.02% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Insiders bought 161,801 shares of company stock valued at $145,621 in the last ninety days. 4.35% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. raised its holdings in TScan Therapeutics by 6.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company’s stock valued at $235,000 after buying an additional 9,676 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new position in TScan Therapeutics in the 2nd quarter valued at approximately $111,000. Vanguard Personalized Indexing Management LLC acquired a new position in TScan Therapeutics in the 2nd quarter valued at approximately $29,000. Marshall Wace LLP bought a new position in shares of TScan Therapeutics during the second quarter valued at $78,000. Finally, Qube Research & Technologies Ltd acquired a new position in shares of TScan Therapeutics during the second quarter worth $99,000. Institutional investors and hedge funds own 82.83% of the company’s stock.

TScan Therapeutics Price Performance

Shares of TCRX stock opened at $1.14 on Friday. The business has a fifty day simple moving average of $1.05 and a 200 day simple moving average of $1.55. The company has a market cap of $64.70 million, a P/E ratio of -1.02 and a beta of 1.04. The company has a quick ratio of 6.44, a current ratio of 6.44 and a debt-to-equity ratio of 0.23. TScan Therapeutics has a twelve month low of $0.88 and a twelve month high of $2.67.

TScan Therapeutics (NASDAQ:TCRX) last released its earnings results on Wednesday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.07. The firm had revenue of $2.51 million for the quarter, compared to analysts’ expectations of $1.98 million. TScan Therapeutics had a negative return on equity of 73.33% and a negative net margin of 1,692.96%. On average, sell-side analysts forecast that TScan Therapeutics will post -1.12 EPS for the current fiscal year.

About TScan Therapeutics

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.